Intriguingly, low-dose osimertinib can inhibit GAPDH activity and tumor endothelial glycolysis, thereby promoting adequate vascularization and immune cell infiltration to improve the tumor repression efficacy of PD-1 blockade (Shan et al., 2022). The gene discussed is PDCD1; the disease is neoplasm.